text stringlengths 1 711 |
|---|
05/08/21 |
06/05/21 |
07/03/21 |
07/31/21 |
08/28/21 |
09/25/21 |
10/23/21 |
11/20/21 |
12/18/21 |
01/15/22 |
02/12/22 |
03/12/22 |
04/09/22 |
05/07/22 |
06/04/22 |
07/02/22 |
07/30/22 |
08/27/22 |
09/24/22 |
10/22/22 |
11/19/22 |
12/17/22 |
01/14/23 |
02/11/23 |
03/11/23 |
04/08/23 |
05/06/23 |
Sales Volume Pricing |
Source: NielsenIQ. J.P. Morgan |
The latest NielsenIQ data points to Zyrtecs consumption up +6.8% (pricing up +10.2% |
while volume down -3.1%) in the latest five-week period ending May 6. This print is an |
acceleration from dollar takeaway up +3.3% (pricing up +7.3%, volume down -3.8%) in |
the 12-week period ending 4/01, and consumption up +3.5% (pricing up +7.6% but |
volume down -3.8%) for the 12-week period ending 12/31/22. However, we note that |
This document is being provided for the exclusive use of DAVID WANG at MARLOWE PARTNERS LP. |
46 |
Andrea Teixeira, CFA AC |
(1-212) 622-6735 |
andrea.f.teixeira@jpmorgan.com |
North America Equity Research |
29 May 2023 J P M O R G A N |
there has been a sequential deceleration on a four-year CAGR basis where Zyrtecs |
takeaway was up +7.8% for the 12-week period ending 12/31, +5.2% for the 12-week |
period ending 4/01, and +4.8% for the five-week period ending 5/06. |
Figure 66: $ Takeaway in Tracked Channels - Zyrtec |
Rolling 12W Period Ending 5/06 |
-20.0% |
-15.0% |
-10.0% |
-5.0% |
0.0% |
5.0% |
10.0% |
15.0% |
20.0% |
25.0% |
30.0% |
01/16/21 |
02/13/21 |
03/13/21 |
04/10/21 |
05/08/21 |
06/05/21 |
07/03/21 |
07/31/21 |
08/28/21 |
09/25/21 |
10/23/21 |
11/20/21 |
12/18/21 |
01/15/22 |
02/12/22 |
03/12/22 |
04/09/22 |
05/07/22 |
06/04/22 |
07/02/22 |
07/30/22 |
08/27/22 |
09/24/22 |
10/22/22 |
11/19/22 |
12/17/22 |
01/14/23 |
02/11/23 |
03/11/23 |
04/08/23 |
05/06/23 |
Sales Volume Pricing |
Source: NielsenIQ. J.P. Morgan |
The most recent tracked channel data shows that headline consumption for Benadryl |
was up +7.4% (pricing up +16.3% but volume down -7.7%) for the five-week period |
ending 5/06, which sequentially accelerated both on a headline and on four-year CAGR |
basis. Benadryls dollar takeaway was up +4.5% (pricing up +12.5%, volume down - |
7.1%) for the 12-week period ending 4/1/23 and was up +2.0% (pricing up +11.2% but |
volume down -8.3%) for the 12-week period ending 12/31/22. As it relates to four-year |
CAGR, takeaway was up +6.3% for the 12-week period ending 12/31, +3.9% for the |
12-week period ending 4/01, and +4.4% for the five-week period ending 5/06. |
Figure 67: $ Takeaway in Tracked Channels - Benadryl |
Rolling 12W Period Ending 5/06 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.